Publications

There are many more publications from the ESLHO networks than currently shown; most of them are mentioned on these 2 pages:

In addition, there are 3 other publications from EuroMRD:

PCR Technology to Identify Minimal Residual Disease.

Cazzaniga G, Songia S, Biondi A; EuroMRD Working Group.

Methods Mol Biol 2021;2185:77-94.

https://pubmed.ncbi.nlm.nih.gov/33165844/

Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.

Pfeifer H, Cazzaniga G, van der Velden VHJ, Cayuela JM, Schäfer B, Spinelli O, Akiki S, Avigad S, Bendit I, Borg K, Cavé H, Elia L, Reshmi SC, Gerrard G, Hayette S, Hermanson M, Juh A, Jurcek T, Chillón MC, Homburg C, Martinelli G, Kairisto V, Lange T, Lion T, Mueller MC, Pane F, Rai L, Damm-Welk C, Sacha T, Schnittger S, Touloumenidou T, Valerhaugen H, Vandenberghe P, Zuna J, Serve H, Herrmann E, Markovic S, Dongen JJMV, Ottmann OG.

Leukemia 2019;33:1910-1922.

https://pubmed.ncbi.nlm.nih.gov/30858550/

Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

Van der Velden VHJ, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, Flohr T, Sutton R, Cave H, Madsen HO, Cayuela JM, Trka J, Eckert C, Foroni L, Zur Stadt U, Beldjord K, Raff T, van der Schoot CE, van Dongen JJM; European Study Group on MRD detection in ALL (ESG-MRD-ALL).

Leukemia 2007;21:604-11.

https://pubmed.ncbi.nlm.nih.gov/17287850/